Citations

Showing 10 of 108094 citations.

Radiographic paradoxical response in metastatic castrate‐resistant prostate cancer (mCRPC) managed with new generation anti‐androgens: a retrospective analysis
Alamiri, Jamal, Britton, Cameron J. , Ahmed, Mohamed E. , Andrews, Jack R. , Higa, Julianna , Dundar, Ayca , Karnes, R. Jeffrey , Kwon, Eugene D., Lowe, Val J. , Bold, Michael S., Pagliaro, Lance C. , Higa, Julianna L , Kendi, Ayse T, Ahmed, Mohamed , Kendi, A. Tuba

Mayo Clinic

The Prostate | September 12, 2022 | Volume: 82 | Issue: 16 | Pages: 1483-1490

10.1002/pros.24413 | PMID 36089822 Get It

AbstractBackgroundProstatic specific antigen (PSA) has well‐recognized limitations as a marker for treatment response and disease progression. Post hoc analysis of the PREVAIL trial reported 24.5% of chemotherapy naïve metastatic castration‐resistant prostate cancer (mCRPC) patients on enzalutamide had radiographic progression on conventional imaging with nonrising PSA. In this study, we sought to study the discordance of imaging with PSA kinetics in mCRPC patients on second generation anti‐androgens (SGA) post‐chemotherapy using combined conventional imaging, and new generation imaging in the form of C‐11 choline positron emission tomography/computed tomography (C[11] choline PET/CT) scan.MethodsWe retrospectively reviewed the medical records of 123 patients with mCRPC treated with SGA (Abiraterone or Enzalutamide) after docetaxel between 2016 and 2019. Patients underwent PSA testing, and C[11] choline PET/CT scan at baseline level before starting treatment with SGA, then every 3–6 months as part of their follow up evaluation. Loss of response to SGA was defined by increase in corrected maximum standardized uptake value (SUVmax) of pretreatment lesions on C‐11 Choline PET/CT, and/or development of new lesions. Suspicious new lesions were confirmed by biopsy and/or conventional imaging.ResultsWe identified 123 mCRPC patients who received SGA (Abiraterone, n = 106; Enzalutamide, n = 17) after docetaxel. Median duration of therapy was 13.9 months (interquartile range: 8.75–21.14). Approximately 43% (n = 53) of subjects in this study exhibited an increase in choline avidity while on SGA. Of this group, 60.4% of patients experienced a parallel rise in PSA (Group‐A), whereas 39.6% displayed a paradoxical response (PR) (Group‐B), defined as increased choline avidity combined with stable or down‐trending PSA. Median PSA at time of increase in choline avidity was 3.1 ng/ml for Group‐A, and 1.3 ng/ml for Group‐B (p = 0.0176). Median SUVmax was similar in both groups (4.9 for Group‐A, 4.6 for Group‐B; p = 0.6072). The median time for increase in choline avidity was 9.5 versus 3.9 months for Group‐A versus Group‐B, respectively (Log‐Rank = 0.0063).ConclusionNearly 40% of mCRPC patients placed on SGA post docetaxel chemotherapy will exhibit paradoxical responses to therapy, therefore, warranting close follow up with imaging. C‐11 choline PET/CT imaging is a useful tool that can help in early predication of disease progression or treatment failure.
Remyelination in neuromyelitis optica spectrum disorder is promoted by edaravone through mTORC1 signaling activation
Luo, Wenjing , Jiang, Wei , Chang, Yanyu , Liu, Chunxin , Tian, Zhenming , Qiu, Xiusheng, Xie, Chichu , Li, Xuejia , Chen, Haijia , Lai, Shuiqing , Wu, Long‐Jun , Cui, Yaxiong , Tang, Changyong , Qiu, Wei , Wu, Long-Jun , Qiu, Wei , Xu, Huiming , Xu, Li , Chen, Chen

Mayo Clinic

Glia | September 12, 2022 | Volume: 71 | Issue: 2 | Pages: 284-304

10.1002/glia.24271 | PMID 36089914 Get It

Abstract Neuromyelitis optica spectrum disorder (NMOSD) is a severe inflammatory autoimmune disease of the central nervous system that is manifested as secondary myelin loss. Oligodendrocyte progenitor cells (OPCs) are the principal source of myelinating oligodendrocytes (OLs) and are abundant in demyelinated regions of NMOSD patients, thus possibly representing a cellular target for pharmacological intervention. To explore the therapeutic compounds that enhance myelination due to endogenous OPCs, we screened the candidate drugs in mouse neural progenitor cell (NPC)‐derived OPCs. We identified drug edaravone, which is approved by the Food and Drug Administration (FDA), as a promoter of OPC differentiation into mature OLs. Edaravone enhanced remyelination in organotypic slice cultures and in mice, even when edaravone was administered following NMO‐IgG‐induced demyelination, and ameliorated motor impairment in a systemic mouse model of NMOSD. The results of mechanistic studies in NMO‐IgG‐treated mice and the biopsy samples of the brain tissues of NMOSD patients indicated that the mTORC1 signaling pathway was significantly inhibited, and edaravone promoted OPC maturation and remyelination by activating mTORC1 signaling. Furthermore, pharmacological activation of mTORC1 signaling significantly enhanced myelin regeneration in NMOSD. Thus, edaravone is a potential therapeutic agent that promotes lesion repair in NMOSD patients by enhancing OPC maturation.
Convalescent plasma and COVID‐19: Time for a second—second look?
Joyner, Michael J. , Carter, Rickey E. , Fairweather, DeLisa , Wright, R. Scott , Fairweather, DeLisa , Carter, Rickey E , Joyner, Michael J

Mayo Clinic

Transfusion Medicine | September 12, 2022 | Volume: 33 | Issue: 1 | Pages: 16-20

10.1111/tme.12915 | PMID 36089562 Get It

AbstractIn this short narrative, we highlight some of our experiences leading the US Convalescent Plasma Program at the beginning of the pandemic in the spring and summer of 2020. This includes a brief summary of how the program emerged and high‐level lessons we learned. We also share our impressions about why convalescent plasma was used at scale in the United States, early in the pandemic and share ideas that might inform the use of convalescent plasma in future outbreaks of novel infectious diseases.
MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls
Gaudioso, Cristina , Mar, Soe , Casper, T. Charles , Codden, Rachel , Nguyen, Adam, Aaen, Gregory , Chitnis, Tanuja , Francisco, Carla , Gorman, Mark , Greenberg, Benjamin , Hart, Janace, Lotze, Timothy , Narula, Sona , Pittock, Sean J. , Rose, John , Schreiner, Teri , Tillema, Jan‐Mendelt , Wheeler, Yolanda , Gaudioso, Cristina M , Chitnis, Tanuja , Graves, Jennifer , Pittock, S J , Waubant, Emmanuelle L. , Greenberg, Benjamin M , Nguyen, Adam, Benson, Leslie, Goyal, Manu S. , Graves, Jennifer , Krupp, Lauren , Rensel, Mary R. , Rodriguez, Moses , Schreiner, Teri , Waldman, Amy , Weinstock‐Guttman, Bianca , Flanagan, Eoin P.

Mayo Clinic

Annals of Neurology | September 11, 2022 | Volume: 93 | Issue: 2 | Pages: 271-284

10.1002/ana.26502 | PMID 36088544 Get It

Objective The purpose of this study was to determine the frequency of myelin oligodendrocyte glycoprotein (MOG)‐IgG and aquaporin‐4 (AQP4)‐IgG among patients with pediatric‐onset multiple sclerosis (POMS) and healthy controls, to determine whether seropositive cases fulfilled their respective diagnostic criteria, to compare characteristics and outcomes in children with POMS versus MOG‐IgG‐associated disease (MOGAD), and identify clinical features associated with final diagnosis. Methods Patients with POMS and healthy controls were enrolled at 14 US sites through a prospective case–control study on POMS risk factors. Serum AQP4‐IgG and MOG‐IgG were assessed using live cell‐based assays. Results AQP4‐IgG was negative among all 1,196 participants, 493 with POMS and 703 healthy controls. MOG‐IgG was positive in 30 of 493 cases (6%) and zero controls. Twenty‐five of 30 patients positive with MOG‐IgG (83%) had MOGAD, whereas 5 of 30 (17%) maintained a diagnosis of multiple sclerosis (MS) on re‐review of records. MOGAD cases were more commonly in female patients (21/25 [84%] vs 301/468 [64%]; p = 0.044), younger age (mean = 8.2 ± 4.2 vs 14.7 ± 2.6 years; p < 0.001), more commonly had initial optic nerve symptoms (16/25 [64%] vs 129/391 [33%]; p = 0.002), or acute disseminated encephalomyelitis (ADEM; 8/25 [32%] vs 9/468 [2%]; p < 0.001), and less commonly had initial spinal cord symptoms (3/20 [15%] vs 194/381 [51%]; p = 0.002), serum Epstein–Barr virus (EBV) positivity (11/25 [44%] vs 445/468 [95%]; p < 0.001), or cerebrospinal fluid oligoclonal bands (5/25 [20%] vs 243/352 [69%]; p < 0.001). Interpretation MOG‐IgG and AQP4‐IgG were not identified among healthy controls confirming their high specificity for pediatric central nervous system (CNS) demyelinating disease. Five percent of those with prior POMS diagnoses ultimately had MOGAD; and none had AQP4‐IgG positivity. Clinical features associated with a final diagnosis of MOGAD in those with suspected MS included initial ADEM phenotype, younger age at disease onset, and lack of EBV exposure. ANN NEUROL 2023;93:271–284
Neuro-oncology at the American Society for Clinical Oncology 2022 Annual Meeting
Lukas, Rimas V. , Chmura, Steven J. , Mammoser, Aaron, Smith, Sonali M. , Parney, Ian F. , Li, Jing

Mayo Clinic

Neuro-Oncology Practice | September 10, 2022 | Volume: 9 | Issue: 6 | Pages: 552-558

10.1093/nop/npac071 | PMID 36388417 Get It

Abstract In the following brief report, we highlight the advances in the neuro-oncology space from the ASCO 2022 Annual Meeting. We put into context the phase 2 and 3 trials and how these may alter the standard of care going forward. In addition, we highlight some other earlier work that will lead to future and potentially practice-changing trials.
Disease Severity in Vaccinated Adults Hospitalized with Breakthrough COVID-19
Finn, Arkadiy , Selvaraj, Vijairam , Jindal, Atin , Lal, Amos , Lal, Amos , Tanzer, Joshua Ray , Dapaah-Afriyie, Kwame

Mayo Clinic

Hospital Topics | September 10, 2022 | Volume: 102 | Issue: 4 | Pages: 223-230

10.1080/00185868.2022.2118093 | PMID 36093610 Get It

Training the next generation of learning health system scientists
Lozano, Paula , Lane‐Fall, Meghan B. , Franklin, Patricia D. , Rothman, Russell L. , Gonzales, Ralph , Ong, Michael , Gould, Michael K. , Beebe, Timothy J. , Roumie, Christianne L. , Mendonça, Eneida A. , Starrels, Joanna L. , Sarkar, Urmimala , Savitz, Lucy A., Moon, JeanHee, Ralston, James D. , Chesley, Francis D. , Lozano, Paula M , Enders, Felicity T, Guise, Jeanne‐Marie , Enders, Felicity , Forrest, Christopher B. , Linzer, Mark

Mayo Clinic

Learning Health Systems | September 10, 2022 | Volume: 6 | Issue: 4 | Pages: No page available

10.1002/lrh2.10342 | PMID 36263260 Get It

AbstractIntroductionThe learning health system (LHS) aligns science, informatics, incentives, stakeholders, and culture for continuous improvement and innovation. The Agency for Healthcare Research and Quality and the Patient‐Centered Outcomes Research Institute designed a K12 initiative to grow the number of LHS scientists. We describe approaches developed by 11 funded centers of excellence (COEs) to promote partnerships between scholars and health system leaders and to provide mentored research training.MethodsSince 2018, the COEs have enlisted faculty, secured institutional resources, partnered with health systems, developed and implemented curricula, recruited scholars, and provided mentored training. Program directors for each COE provided descriptive data on program context, scholar characteristics, stakeholder engagement, scholar experiences with health system partnerships, roles following program completion, and key training challenges.ResultsTo date, the 11 COEs have partnered with health systems to train 110 scholars. Nine (82%) programs partner with a Veterans Affairs health system and 9 (82%) partner with safety net providers. Clinically trained scholars (n = 87; 79%) include 70 physicians and 17 scholars in other clinical disciplines. Non‐clinicians (n = 29; 26%) represent diverse fields, dominated by population health sciences. Stakeholder engagement helps scholars understand health system and patient/family needs and priorities, enabling opportunities to conduct embedded research, improve outcomes, and grow skills in translating research methods and findings into practice. Challenges include supporting scholars through roadblocks that threaten to derail projects during their limited program time, ranging from delays in access to data to COVID‐19‐related impediments and shifts in organizational priorities.ConclusionsFour years into this novel training program, there is evidence of scholars' accomplishments, both in traditional academic terms and in terms of moving along career trajectories that hold the potential to lead and accelerate transformational health system change. Future LHS training efforts should focus on sustainability, including organizational support for scholar activities.
MANAGEMENT OF THE PATIENT WITH CHRONIC CRITICAL ILLNESS – PART 2
Finn, Arkadiy , Selvaraj, Vijairam , Peterson, Elijah, Banerjee, Debasree, Lal, Amos , Martin, Edward, Dapaah-Afriyie, Kwame , Lal, Amos , Banerjee, Debasree , Grewal, Himmat

Mayo Clinic

Journal of Community Hospital Internal Medicine Perspectives | September 10, 2022 | Volume: 12 | Issue: 5 | Pages: 6-10

10.55729/2000-9666.1066 | PMID 36262490 Get It

Patients with chronic critical illness (CCI) represent a growing segment of the hospitalized population. Key aspects of care in CCI patients including tracheostomy, prolonged mechanical ventilation, nutritional support, wound care, and others require a comprehensive, goal-directed approach. Infectious complications of CCI including pneumonia, tracheobronchitis and urinary tract infection may be caused by nosocomial organisms requiring awareness and adjustment of treatment regimen. Finally, psychiatric, palliative, rehabilitative components of care impact heavily upon outcomes in CCI patients. As care that is typically associated with the intensive care unit is extended to the hospital ward, we aim to increase awareness among providers and outline a systematic approach to deliver high quality, patient centered care to CCI patients
A Rare Case of Pembrolizumab Associated Encephalopathy
Basnet, Sijan , Singh, Rajanbir, Tharu, Biswaraj , Pawar, Tushar, Basnet, Garima

Mayo Clinic

Journal of Community Hospital Internal Medicine Perspectives | September 10, 2022 | Volume: 12 | Issue: 5 | Pages: 57-59

10.55729/2000-9666.1091 | PMID 36262501 Get It

We present a unique case of a 55-year-old man with confusion thought to be due to pembrolizumab which he was receiving for renal cell carcinoma. His workup for other possible etiologies for encephalopathy was negative. He was treated with high dose intravenous methylprednisolone followed by prednisone taper and intravenous immunoglobulin with gradual improvement in his mentation.
Autologous Umbilical Cord Blood–Derived Mononuclear Cell Therapy Promotes Cardiac Proliferation and Adaptation in a Porcine Model of Right Ventricle Pressure Overload
Oommen, Saji , Peral, Susana Cantero, Qureshi, M. Yasir , Holst, Kimberly , Burkhart, Harold M. , Hathcock, Matthew , Kremers, Walter K. , Brandt, Emma B. , Larsen, Brandon T. , Edwards, Brooks S., Maleszewski, Joseph J. , Cantero Peral, Susana, Qureshi, Muhammad Y , Holst, Kimberly A, Kremers, Walter K , Dearani, Joseph A. , Nelson, Timothy J.

Mayo Clinic

Cell Transplantation | September 10, 2022 | Volume: 31 | Issue: No issue available | Pages: No page available

10.1177/09636897221120434 | PMID 36086821 Get It

Congenital heart diseases, including single ventricle circulations, are clinically challenging due to chronic pressure overload and the inability of the myocardium to compensate for lifelong physiological demands. To determine the clinical relevance of autologous umbilical cord blood–derived mononuclear cells (UCB-MNCs) as a therapy to augment cardiac adaptation following surgical management of congenital heart disease, a validated model system of right ventricular pressure overload due to pulmonary artery banding (PAB) in juvenile pigs has been employed. PAB in a juvenile porcine model and intramyocardial delivery of UCB-MNCs was evaluated in three distinct 12-week studies utilizing serial cardiac imaging and end-of-study pathology evaluations. PAB reproducibly induced pressure overload leading to chronic right ventricular remodeling including significant myocardial fibrosis and elevation of heart failure biomarkers. High-dose UCB-MNCs (3 million/kg) delivered into the right ventricular myocardium did not cause any detectable safety issues in the context of arrhythmias or abnormal cardiac physiology. In addition, this high-dose treatment compared with placebo controls demonstrated that UCB-MNCs promoted a significant increase in Ki-67-positive cardiomyocytes coupled with an increase in the number of CD31+ endothelium. Furthermore, the incorporation of BrdU-labeled cells within the myocardium confirmed the biological potency of the high-dose UCB-MNC treatment. Finally, the cell-based treatment augmented the physiological adaptation compared with controls with a trend toward increased right ventricular mass within the 12 weeks of the follow-up period. Despite these adaptations, functional changes as measured by echocardiography and magnetic resonance imaging did not demonstrate differences between cohorts in this surgical model system. Therefore, this randomized, double-blinded, placebo-controlled pre-clinical trial establishes the safety of UCB-MNCs delivered via intramyocardial injections in a dysfunctional right ventricle and validates the induction of cardiac proliferation and angiogenesis as transient paracrine mechanisms that may be important to optimize long-term outcomes for surgically repaired congenital heart diseases.